Johnson & Johnson (JNJ)vsKestra Medical Technologies, Ltd. Common Stock (KMTS)
JNJ
Johnson & Johnson
$255.56
+0.90%
HEALTHCARE · Cap: $613.99B
KMTS
Kestra Medical Technologies, Ltd. Common Stock
$27.24
-5.02%
HEALTHCARE · Cap: $1.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 91657% more annual revenue ($97.93B vs $106.73M). JNJ leads profitability with a 21.5% profit margin vs -140.4%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
KMTS
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.1%
Fair Value
$141.74
Current Price
$255.56
$113.82 premium
Intrinsic value data unavailable for KMTS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Revenue surging 59.9% year-over-year
Areas to Watch
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -50.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : KMTS
The strongest argument for KMTS centers on Revenue Growth. Revenue growth of 59.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : KMTS
The primary concerns for KMTS are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while KMTS is a hypergrowth play — different risk/reward profiles.
KMTS is growing revenue faster at 59.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 28/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Kestra Medical Technologies, Ltd. Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?